HLS Therapeutics Inc. (OTCMKTS:HLTRF – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $3.09 and traded as low as $2.73. HLS Therapeutics shares last traded at $2.73, with a volume of 100 shares traded.
Analyst Upgrades and Downgrades
Separately, Raymond James Financial raised HLS Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Thursday, August 13th. One analyst has rated the stock with a Strong Buy rating. According to MarketBeat, HLS Therapeutics has an average rating of “Strong Buy”.
Get Our Latest Analysis on HLS Therapeutics
HLS Therapeutics Trading Down 14.7%
The company’s fifty day moving average is $2.87 and its 200 day moving average is $3.09.
About HLS Therapeutics
HLS Therapeutics Inc. is a specialty pharmaceutical company focused on acquiring, licensing, developing and commercializing prescription medicines. Rather than primarily discovering new drugs, the company generally builds value by obtaining rights to established or differentiated pharmaceutical products and supporting their regulatory approval, market access and commercial distribution. The company’s activities have centered on specialty-care and hospital-related therapies, including products for central nervous system and cardiovascular conditions.
Recommended Stories
- Five stocks we like better than HLS Therapeutics
- Checkmate for AI Chips? NVIDIA’s Crisis Opens the Board
- Can NVIDIA Maintain Its Momentum Without Huang?
- Six Flags Lost $366 Million in Q3—Its Insiders Just Went Shopping
- What Went Wrong With Amprius Technologies’ Q3? Less Than You’d Think
Receive News & Ratings for HLS Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HLS Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
